A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib
Tóm tắt
Cyclosporine A (CsA) and imatinib are both CYP3A4 and P-glycoprotein substrates. Concomitant use after hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (ALL) may therefore result in a pharmacokinetic interaction. Although case reports and a recent small study in children indeed suggested there is a relevant pharmacokinetic interaction, a larger study in adults is lacking. In this study, we assessed the presence and extent of this interaction in patients with CML or Ph+ ALL undergoing HSCT. From a large database containing data of all patients receiving HSCT in our center between 2005 and 2015, we selected 16 patients using this drug combination. The average dose-corrected CsA concentration was calculated before and after initiation of imatinib. The average dose-corrected CsA concentration increased during imatinib use in all patients, on average by 94 % (p < 0.001). Based on measured drug concentrations, the CsA dosage needed to be reduced, on average, by 27 % after initiation of imatinib (p = 0.004). Imatinib significantly increases CsA concentrations in HSCT patients, putting these patients at increased risk of CsA toxicity. We recommend intensive monitoring of CsA concentrations after initiation of imatinib; a pre-emptive CsA dose reduction of 25 % might be considered.
Từ khóa
Tài liệu tham khảo
Beauchesne PR, Chung NS, Wasan KM (2007) Cyclosporine A: a review of current oral and intravenous delivery systems. Drug Development and Industrial Pharmacy 33(3):211–220. doi:10.1080/03639040601155665
Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990) Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products. Science (New York, NY) 247(4946):1079–1082
Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA (2011) Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 117(8):e75–e87. doi:10.1182/blood-2010-07-294330
Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1(7):493–502. doi:10.1038/nrd839
Carpenter PA, Snyder DS, Flowers ME, Sanders JE, Gooley TA, Martin PJ, Appelbaum FR, Radich JP (2007) Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood 109(7):2791–2793. doi:10.1182/blood-2006-04-019836
Kajita T, Higashi Y, Imamura M, Maida C, Fujii Y, Yamamoto I, Miyamoto E (2006) Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats. The Journal of Pharmacy and Pharmacology 58(7):997–1000. doi:10.1211/jpp.58.7.0016
Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T (2007) INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 109(1):306–314. doi:10.1182/blood-2006-03-013250
Yamada M, Miyamura K, Fujiwara T, Yokoyama H, Tomiya Y, Ishizawa K, Harigae H, Kameoka J, Sasaki T (2004) Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: report of 4 cases. Tohoku J Exp Med 204(1):79–84
Mulder KE, Egorin MJ, Sawyer MB (2012) Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib. Investig New Drugs 30(6):2400–2402. doi:10.1007/s10637-011-9769-3
Bleyzac N, Kebaili K, Mialou V, Bertrand Y, Goutelle S (2014) Pharmacokinetic drug interaction between cyclosporine and imatinib in bone marrow transplant children and model-based reappraisal of imatinib drug interaction profile. Ther Drug Monit 36(6):724–729. doi:10.1097/ftd.0000000000000084
Bruggemann RJ, Alffenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM (2009) Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society Of America 48(10):1441–1458. doi:10.1086/598327
Peng B, Knight H, Riviere GJ, Rouilly M, Brown AK, Lane A, Amakye D, Burtin P (2002) Pharmacokinetic interaction between Gleevec (TM) (imatinib) and cyclosporin. Blood 100(11):433B–434B
Lindholm A (1991) Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 13(6):465–477
Zhou SF, Xue CC, Yu XQ, Li C, Wang G (2007) Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29(6):687–710. doi:10.1097/FTD.0b013e31815c16f5
Lempers VJ, Martial LC, Schreuder MF, Blijlevens NM, Burger DM, Aarnoutse RE, Bruggemann RJ (2015) Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice. Curr Opin Pharmacol 24:38–44. doi:10.1016/j.coph.2015.07.002
Scarisbrick JJ, Dignan FL, Tulpule S, Gupta ED, Kolade S, Shaw B, Evison F, Shah G, Tholouli E, Mufti G, Pagliuca A, Malladi R, Raj K (2015) A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent. Bone Marrow Transplant 50(1):62–67. doi:10.1038/bmt.2014.227
Woillard JB, Lebreton V, Neely M, Turlure P, Girault S, Debord J, Marquet P, Saint-Marcoux F (2014) Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients. Br J Clin Pharmacol 78(4):836–846. doi:10.1111/bcp.12394